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Chitosan based porous scaffolds are of great interest in biomedical applications especially in tissue en-
gineering because of their excellent biocompatibility in vivo, controllable degradation rate and tailorable
mechanical properties. This paper presents a study of the fabrication and characterization of bioactive
scaffolds made of chitosan (CS), carboxymethyl chitosan (CMC) and magnesium gluconate (MgG).
Scaffolds were fabricated by subsequent freezing-induced phase separation and lyophilization of poly-
electrolyte complexes of CS, CMC and MgG. The scaffolds possess uniform porosity with highly inter-
connected pores of 50e250 mm size range. Compressive strengths up to 400 kPa, and elastic moduli up to
5 MPa were obtained. The scaffolds were found to remain intact, retaining their original three-
dimensional frameworks while testing in in-vitro conditions. These scaffolds exhibited no cytotoxicity
to 3T3 ﬁbroblast and osteoblast cells. These observations demonstrate the efﬁcacy of this new approach
to preparing scaffold materials suitable for tissue engineering applications.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Tissue defects and diseases due to trauma, injuries, infections,
degeneration, and congenital deformity are a major human health
concern. These problems underscore the need for improved tissue
regeneration treatment technologies. There has been some recent
progress in organ transplantation and surgical reconstruction.
Smaller sized defects are best treated by surgical reconstruction,
using the ability of tissue to regenerate and spontaneously heal
over time. Defects larger than a critical size require a scaffold, or
substrate, to support the cell growth and guide the repair process.
The current clinical approach mostly involves the use of autografts
(from the patient's own tissue) and allografts (tissue other than the
patient's own). Several considerations limit the use of these tech-
niques: signiﬁcant morbidity-related complications at the tissueiological and Bioengineering,
USA.
nications Co., Ltd.
ing by Elsevier B.V. on behalf of Ke
d/4.0/).donation site in the body, the unavailability of matching donor
tissue, risk of disease transmission and immune rejection [1e3].
Tissue engineering is evolving as a third approach to overcome
these limitations and to develop viable grafts. With this approach,
new tissue can be regenerated using a synthetic scaffold as a sub-
strate to promote cell adhesion and proliferation. The scaffold
material is designed to biodegrade in a controlled fashion, leaving
the space for newly formed tissues [3e6]. The repair process can
further be aided by loading drugs and growth factors into such
scaffolds [3].
The material properties ideally required for tissue regeneration
scaffold drive the choice of material. A partial listing of these
properties is: uniform porosity with macro as well as micro-sized
pores, non-toxicity to the host tissue, biodegradation and bio-
resorption, and sufﬁcient mechanical properties [7]. Macropores
are required for cell and blood vessels to grow and migrate [8],
whereas micropores play a vital role in cell-cell communication,
and nutrient transport and removal of waste products [9,10]. Most
current candidate materials fail to satisfy all the requirements, due
either to insufﬁcient strength during implantation, or the inability
to degrade at same rate as that of new tissue growth. If the tissuesAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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they will not be able to bear the physiological stresses of post-
treatment use. The composites of biodegradable natural polymers
and ceramics come closest to fulﬁlling most of these property re-
quirements. The organic polymer phase enhances the biodegra-
dation needed to provide the space for tissue growth. The dispersed
phase provides the required mechanical integrity to the scaffold
[11,12].
Chitosan, made of glucosamine and N-acetylglucosamine units
linked by one to four glycosidic bonds, has been proven to be bio-
logically renewable, biodegradable, biocompatible, nonantigenic,
nontoxic, biofunctional. Also, it also bears the proxy structure of
glycosaminoglycan (GAG), a major component that constitutes the
tissue extracellular matrix (ECM) [13e15]. Chitosan and some of its
complexes have also been studied for use in a number of other
biomedical applications, including wound dressings, drug delivery
systems, and space-ﬁlling implants [16,17]. However, the major
drawback of chitosan is its lack of proper mechanical strength for
hard tissue engineering applications. Several studies have been
conducted to improve its strength by reinforcing it with various
ceramic phases like wollastonite, hydroxyapatite and beta tri-
calcium phosphate (b-TCP) and also by polyblending with other
synthetic and natural polymers [18]. In this study, chitosan was
combined with its oppositely-charged derivative, carboxymethyl
chitosan (CMC) to form a stable matrix phase and magnesium
gluconate (MgG) as the dispersed phase. MgG is an organic salt of
magnesium that readily dissolves to release Mgþþ ions. A number
of studies have demonstrated that divalent cations such as Mgþþ,
Caþþ, and Mnþþ play a critical role in tissue remodeling and
development [19e21]. The extracellular matrix (ECM) of tissue
contains certain domains that bind divalent cations such as Caþþ,
Mgþþ and Mnþþ. These ECM-bound cations modify the integrin
afﬁnity to their respective ligands [20,22e24]. In a study performed
by Zreiqat et al., human bone-derived cells grown on bioceramic
substrate modiﬁed with divalent cations showed higher expression
levels of b1-, a5, a5a1-, and a3b1-integrin receptors, compared to
Mgþþ free substrates [20]. The choice of Mg for use in implants is
further motivated by magnesium's excellent biocompatibility,
degradation into non-toxic products and its proven use as an
essential nutrient for human metabolism [25].
A porous and bioactive scaffolds was fabricated by using a blend
mixture of CS, CMC and MgG, and subsequent freezing-induced
phase separation and lyophilization. Magnesium gluconate was
ﬁrst introduced into aqueous solution of CMC and mixed the
resulted solutionwith CS solution in acidic pH prior to freezing and
lyophilization to obtain the composite the scaffolds. Scaffold
morphology was analyzed by SEM, water uptake and retention
ability by weighing the amount of water absorbed and retained
after centrifugation and cell toxicity using 3T3 ﬁbroblast and
osteoblast cells. Mechanical properties of scaffolds were evaluated
under compression loading. Additionally, a release study was car-
ried out at different time points using UV-VIS spectrophotometry to
quantify the amount of Mgþþ released from the chitosan-CMC-
based composite scaffolds.
2. Materials and methods
2.1. Materials
Chitosan powder (Medium Mw, DD 75e85%) was purchased
from Sigma-Aldrich (St. Louis, MO, USA) and carboxymethyl chi-
tosan (CMC) powder (DD 90%) was purchased from Santa Cruz
Biotechnology (Dallas, TX, U.S.A.). Magnesium gluconate dihy-
drate (MgG) was purchased from Pfaltz & Bauer (Waterbury, CT,
USA). Glacial acetic acid and sodium hydroxide (NaOH) werepurchased from Acros Organics (Morris Plains, NJ, USA). Phos-
phate buffered saline (PBS) was purchased from Thermo Fisher
Scientiﬁc (Fair Lawn, NJ, USA). Alamar blue and Xylidyl blue assay
kits were obtained from Stanbio Laboratory (Boerne, TX, USA) and
Life Technologies (Grand Island, NY, USA) respectively. (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT)
assay kit was obtained from Sigma-Aldrich (Oakville, ON,
Canada).
2.2. Fabrication of scaffolds
Chitosan solution and CMC solutions were prepared at con-
centrations of 2, 4 and 5 wt%. Chitosan was dissolved in 2% acetic
acid. CMC was dissolved in deionized (DI) water. The two solutions
were thoroughly mixed in a 1:1 wt ratio in a container rotating
inside a Thinky planetary centrifugal mixer (Planetary Centrifugal
Mixer, ARM-310) for 30 min at 2000 rpm (Fig. 1). After thorough
mixing, the material was injected via syringe in 48-well cell culture
dishes. The cast material was kept at 4 C for about 30 min,
transferred to 20 C for 4 h, and ﬁnally to 80 C for 12 h. The
scaffolds were allowed to lyophilize for about 36 h in the freeze
dryer (LabConCo, Kansas City, MO). Excess acetic acid in the dried
scaffolds was neutralized by immersing the scaffolds in 0.1 M so-
dium hydroxide (NaOH) solution for 15 min and then washing
thrice with DI water.
As in Table 1, two sets of scaffolds were prepared. For the ﬁrst
set of scaffolds, three concentrations of polymer solutions were
used, with no added MgG. For the second set of scaffolds, polymer
concentration of CS and CMC was held constant at 5% and the
relative amount of MgG was varied. The quantity of MgG added to
the scaffolds was 5%, 10%e20% of the total weight of the chitosan
and CMC dry powder present in the solution. This was done by
dissolving the MgG in 2 ml of DI water and then mixing it with the
CMC solution. CMC and MgG were allowed to mix in the Thinky
mixer for 15 min at 2000 rpm. CS solution was then added to the
CMC e MgG system and allowed to crosslink in the Thinky for
30 min at 2000 rpm. The process of casting, freezing, lyophiliza-
tion and neutralization was repeated similarly. To measure the
required weight (W) of MgG in grams, the following equation was
used.
WMgG ¼
%MgG
100
*½C1*V1 þ C2*V2 (1)
where, C1 and C2 are the concentrations in wt% while V1 and V2 are
the volumes (in ml) of CS and CMC solutions, respectively.
2.3. Study of morphology and pore size distribution
The surface morphology of the scaffolds was studied by scan-
ning electronmicroscopy (SEM) (Hitachi SU8000, Japan). Thin discs
of ~1 mm thickness were cut from the scaffolds using surgical
scalpel. The samples were mounted on the holder with double-
sided carbon tape and sputter-coated with gold using a Polaron
SEM coating system (Quorum Technologies, East Sussex, UK) for
2 min at 15 mA. The SEM images were taken at an accelerating
voltage of 2 kV and current of 5 mA. Scaffold pore size distributions
were evaluated using Image J software (NIH, Gaithersburg, MD)
according to previous method on the SEM images [26]. The scale
bar length is measured in pixels. Three different images were
analyzed for each scaffold composition.
2.4. Water uptake and retention abilities
Water absorption efﬁciency was determined as follows: initial
Fig. 1. Schematic ﬂow process showing steps in the fabrication of chitosan scaffolds.
Table 1
Table showing the composition of various scaffolds fabricated.
Sample Chitosan concentration
(wt%) in dil. acetic acid
CMC concentration
(wt%) in DI water
Chitosan
CMC w ratio
Ratio of chitosan þ CMC to MgG
Set A
A. CS/CMC (2%) 2 2 1:1 NA
B. CS/CMC (4%) 4 4 1:1 NA
C. CS/CMC (5%) 5 5 1:1 NA
Set B
D. CS/CMC (5%) MgG (5%) 5 5 1:1 1:0.05
E. CS/CMC (5%) MgG (10%) 5 5 1:1 1:0.1
F. CS/CMC (5%) MgG (20%) 5 5 1:1 1:0.2
U. Adhikari et al. / Bioactive Materials 1 (2016) 132e139134dry weight (Wd) of the as-prepared scaffold was measured using an
electronic balance. The scaffold was neutralized using NaOH to
remove any acetate formed during fabrication. It was then
immersed in 30mL DI water at 37 C for 24 h, after which theywere
blotted with ﬁlter paper to remove excess surface water. The
swollen scaffold weight (Ws) was recorded. The equilibrium water
absorption (EA, %) was calculated as:EA ¼
Ws Wd
Wd
X100 (2)
The water retention efﬁciency was determined as follows: the
swollen scaffold was transferred to a centrifuge tube with ﬁlter
paper at the bottom, centrifuged at 500 rpm for 3 min, and then
U. Adhikari et al. / Bioactive Materials 1 (2016) 132e139 135immediately weighed (Ww).Water retention (ER, %) efﬁciency of the
scaffold at equilibrium was calculated as:
ER ¼
Ww Wd
Wd
X100 (3)
2.5. Mechanical testing
The mechanical testing of the as-prepared scaffolds was per-
formed with an Instron 5542 (Instron Corporation, Canton, MA,
USA) using 500 N load cell. After measuring the initial dimensions,
the samples were tested for failure under a compressive load.
Samples were tested at a displacement rate of 0.5 mm per minute.
The test was stopped at 50% reduction in sample height. Load and
displacement data collected by the test machine's Merlin software
were utilized to compute the strains and the corresponding stress
values. These values were plotted using Origin software to obtain
the strain-stress graph for individual samples. The failure point in
compression was located by using 0.2% offset in the strain value.
The stress at this failure point and the slope of the initial linear
region were recorded as the compressive stress and compressive
modulus.
2.6. Magnesium release study
The magnesium (Mgþþ) release proﬁle was studied for 5% CS/
CMC scaffolds with 5, 10 and 20% MgG concentrations. The release
study was carried out by using published protocol of Magnesium
Colorimetric Xylidyl Blue Assay (Stanbio Laboratory, Boerne, TX,
USA) [27]. The dry weight of each scaffold was measured before
neutralizing with NaOH. Neutralized scaffolds were placed in a tube
containing 30 ml of 1X PBS solution which was incubated in a
Dubnoff Metabolic Shaking Incubator at 37 C and 30 rpm. 10 mL of
ﬂuid was withdrawn from the tube at speciﬁed time intervals and
added to 1ml of Xylidyl Blue reagent in a cuvette. After allowing the
reagent to react with the sample for 60 min, the absorbance of each
sample was measured by a GENESYS 10S UV-VIS Spectrophotom-
eter at 520 nm. The concentration of (Mgþþ) ions in the solution
was calculated from a standard calibration curve previously pre-
pared by using the known concentration of MgG solutions in 1X
PBS solution.
2.7. Cell culture and seeding
Scaffolds were cut into 2-mm-thick circular discs and then
neutralized with NaOH. Samples were sterilized in 24-well plates
by incubating in 95% ethanol for at least 30 min under sterile fume
hood. After 30min, samples were rinsed with sterile DI water twice
and 1X DPBS once.
NIH/3T3 cells (a mouse ﬁbroblast cell line) and Osteoblast cells
(Homo Sapien bone cell line CRL-11372) were purchased from the
American Tissue Type Culture Collection (Manassas, VA). The NIH/
3T3 cells were cultured in a 75 cm2 culture ﬂask with one mL of the
growth medium, Dulbecco's modiﬁed Eagle's medium (DMEM)
(Life Technologies, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotics (10,000 units/mL of peni-
cillin and 10,000 mg/mL of streptomycin) at 37 C and 5% CO2. The
culture media for osteoblast cells was DMEM supplemented with
10% FBS and 1% Genticin. The culture mediumwas replaced every 2
days. After reaching about 90% conﬂuence, the cells were detached
by 0.025% trypsin and 0.01% EDTA in PBS solution and transferred
to centrifuge tube containing culture medium. After centrifugation,
the cells were suspended in fresh culture medium and countedusing a hemocytometer before seeding to samples. An aliquot of
medium containing cells (~50,000 ﬁbroblasts and ~100,000 oste-
oblasts per samples) was seeded on the scaffold samples (n ¼ 3)
and grown in a humidiﬁed incubator (37 C, 5% CO2) for 72 h.2.8. Alamar Blue assay
In vitro cytotoxicity was studied by using an Alamar Blue (AB)
colorimetric assay (Life Technologies, Grand Island, NY) according
to previous publication [6,28]. After 1 and 3 days of incubation, the
culture plates were taken out from the incubator and media was
removed. Each sample was washed twice with DPBS and incubated
with 10% AB containing DMEM supplemented with 10% FBS and 1%
antibiotics for 2 h. 1 mL of 10% AB was placed in each well plate. A
400-mL sample of the assay solution was removed from the wells
and transferred to an opaque 96-well culture plate for ﬂuorescent
measurements on a Spectra max Gemini XPS microplate reader
(Molecular Devices, Sunnyvale, CA) at lex 530 nm, lem 590 nm. The
relative ﬂuorescent units were converted to a percent of the
average values for cells in control wells.2.9. Cell metabolic activity assay-MTT
The metabolic activity of osteoblast cells when cultured on
scaffolds was analyzed by using MTT assay. After 1 and 3 days of
incubation, cell seeded scaffolds were transferred into a fresh
multi-well plate and 100 mL of fresh medium was added to them.
10 mL of 12 mM MTT solution was added to each well plate and
incubated at 37 Cwith 5% CO2 for 4 h. 500 mL of DMSO solutionwas
added to dissolve the precipitated purple colored formazan crystals
and the absorbance was recorded at 540 nm by using a Clariostar
monochromator microplate reader (BMG Labtech, Ortenberg,
Germany).2.10. Statistical analysis
Each experiment was carried out for n ¼ 3. Values are presented
as a mean of 3 readings ± standard deviation of these readings.
Mean values were compared by one-way analysis of variance
(ANOVA). Tukey's post hoc test was performed for comparison using
Origin software considering P < 0.05 to be statistically signiﬁcant.3. Results
3.1. Morphology and pore size distribution
Morphology and size distribution of as-synthesized porous 3D
scaffolds were assessed by using SEM images (Fig. 2). SEM analysis
showed that the scaffolds did have uniform porosity with pore size
in the range of 50e150 mm for 4% CS/CMC and 5% CS/CMC scaffolds
and 150e250 mm for 2% CS/CMC. Analysis showed that the pore size
of 4% CS/CMC and 5% CS/CMC scaffolds were not signiﬁcantly
different at the 0.05 level of statistical signiﬁcance. However, these
two sets of scaffolds showed signiﬁcantly different pore size range
from the 2% CS/CMC scaffolds at the same 0.05 level. For the 5% CS/
CMC scaffolds containing 5%, 10% and 20% of MgG, not much dif-
ference in the morphology and pore size was observed (Fig. 3). This
100e150 mm pore size range is very beneﬁcial for cell growth [29].
The micrographs also show the small inner pores throughout the
structure of the scaffolds. These interconnected pores are required
for the cells to communicate freely while the scaffolds are being
used for tissue regeneration application.
Fig. 2. SEM images AeC: scaffolds containing 2% (A), 4% (B), and 5% (C) of CS/CMC with no MgG; and DeF: 5% CS/CMC containing relative amounts of 5% (D), 10% (E), and 20% (F)
MgG respectively. The scale bar represents 500 mm; image taken at 100 magniﬁcation.
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The water uptake and retention ability of the six types of scaf-
folds are seen in Fig. 4. Increasing the polymer as well as MgG
concentrations lead to a decrease in the degree of water absorption.
The water retention ability of CS/CMC scaffolds, however, is seen to
increase with increase in the polymer concentration. The water
retention ability of 5% CS/CMC scaffolds with no MgG as well as
with 5, 10, 20% MgG were found to be comparable, with very slight
differences.
3.3. Mechanical properties
The results of the compression test are presented in Fig. 5. The
compressive strength of the scaffolds was found to increase from
0.04 MPa to 0.25 MPa (520% increase) as the concentration of CS/
CMC polymer was increased from 2 wt% to 5 wt%. Addition of 5%
MgG to the 5 wt% CS/CMC scaffold also increased the strength from
0.25 to 0.34 MPa (36% increase). However, there was only a mar-
ginal increase in strength of 5 wt% CS/CMC scaffolds from 0.34 to
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U. Adhikari et al. / Bioactive Materials 1 (2016) 132e139 1370.38 MPa (12%) as the relative amount of MgG was increased from
5% to 20%. Similar trends were observed when the compressive
modulus of different CS/CMC scaffolds was compared. Compressive
modulus was increased from 0.45 MPa to 3.2 MPa (610% increase)
when the polymer concentration was increased from 2 wt% to 5 wt
% CS/CMC. A further 68% improvement in compressive modulus
was observed when 5% MgG was added to 5 wt% CS/CMC scaffolds.
There was not much change in the modulus when the amount of
MgG was increased to 10% but a sharp increase of 1.6 MPa (30%) in
modulus when the MgG amount was increased to 20%.0
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Fig. 7. In vitro cytotoxicity for Fibroblast 3T3 cells, a mouse ﬁbroblast cell line in CS/
CMC scaffolds with varying amounts of MgG. The data are presented as the means ± SD
(n ¼ 3). *p < 0.05 compared to 5% CS/CMC (no MgG).3.4. Magnesium release study
The magnesium ion (Mgþþ) release proﬁles of 5 wt% CS/CMC
scaffolds containing 5, 10 and 20% MgG are shown in Fig. 6. The
results were obtained in terms of cumulative concentration of
magnesium ions at that point in time. Each data point represents
the mean of three independent samples. All the scaffolds with
different MgG concentrations had similar release proﬁles. The
release proﬁles of scaffolds showed the sustained release of mag-
nesium ions. The rate of release of magnesium ions from the CS/CMCmatrix was initially rapid and then slowed down signiﬁcantly.
No signiﬁcant differences in magnesium release proﬁle were
observed (at the p < 0.05 level) between three MgG concentration
levels after 154 h. After 154 h, 0.31 mM (70%), 0.57 mM (72%) and
1.3 mM (75%) of Mgþþ was released from 5%, 10% and 20% MgG
scaffolds, respectively.3.5. Alamar Blue assay (3T3 ﬁbroblast cells)
Fig. 7 shows the changes in relative levels of AB between 3T3
cells grown on Mg scaffold's surface and on the control substrate
(5% CS/CMC (no MgG)). After day 1, the average cell viability for 5%
CS/CMC scaffolds with 5, 10 and 20% MgG were found to be 100, 89
and 91% respectively. Similarly, after day 3, these scaffolds exhibi-
ted 88, 95 and 90% cell viability respectively as compared to control
substrate.
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Fig. 8 shows the changes in relative cell viability between
osteoblast cells grown on Mg scaffold's surface and on the control
substrate (no Mg present). After day 1, the average cell viability for
5% CS/CMC scaffolds with 5, 10 and 20% MgG were found to be 149,
138 and 115% respectively. Similarly, after day 3, these scaffolds
exhibited 119, 101 and 101% cell viability respectively as compared
to control substrate. The culture media has pH change from 7.36 up
to 8.58 and 8.95 after day 1 and 3 respectively (supplementary
Table 1). Similar to the results obtained with 3T3 ﬁbroblast cells,
cytotoxicity on the Mg-containing scaffold materials were minimal
as compared to control substrate which shows that these scaffolds
are nontoxic and can provide adequate support for osteoblast cell
growth and proliferation.
4. Discussions
Tissue engineering has beenwidely regarded as an alternative to
the traditional autograft and allograft approaches to tissue repair.
For successful regeneration of damaged tissue, it is essential to
select the proper components to develop a scaffold. Chitosan (CS) is
the most-examined among other various available natural poly-
mers, such as alginate, hyaluronic acid, collagen, ﬁbrin, and silk,
because of its proven minimal foreign body response, biodegra-
dation into non-toxic products, intrinsic antibacterial nature and
low cost [30,31]. In this research, CS was mixed with its negatively-
charged derivative CMC to obtain a complex coacervate that, after
lyophilization, resulted in a stable scaffold structure. CS and CMC
have similar structure but opposite electric charge, which enables
them to interact strongly and form polyelectrolyte network struc-
ture [32]. Simultaneously, MgG was added in to the mixture of CS
and CMC so that MgG-incorporated CS/CMC scaffolds were formed.
This is believed to improve osteoblast adhesion properties while it
releases divalent Mgþþ ions in aqueous medium. Overall, through
this process, we obtained a bioactive CS/CMC-MgG composite in
the form of porous scaffold.
The composite scaffolds developed in this study have pore size
of 50e250 mm. These pores were highly interconnected with 3D
porous network structures (supplementary Fig. 1). The porous
structure of the CS/CMC based composite scaffolds was achievedthrough a process of thermally-induced phase separation and
subsequent sublimation of the solvent. This porous structure allows
the passage of nutrients and metabolites as well as provides sites
for cell attachment and proliferation [32,33].
During the early stages of the scaffold implantation, it is
essential for the scaffold to absorb physiological ﬂuids and the
nutrients for consumption by the colonizing osteoblast cells [34].
Hence in the process of developing a tissue engineered scaffold, the
water absorption and retention capacities are important factors.
The results of water uptake and retention studies suggested that
the scaffolds in the present study had the capacity to retain more
water than their own weight, as both values were more than 100%.
Both the hydrophilic nature of CS and its ability to maintain a 3D
structure contribute to the swelling abilities of these scaffolds.
An ideal tissue engineering scaffold should be biocompatible
and highly porous and have adequate mechanical properties. The
mechanical properties of the synthetic material should be close to
those of the target tissue in order to avoid the stress-shielding ef-
fect. This allows the scaffold to maintain structural integrity in both
in vivo and in vitro applications. Mechanical properties also inﬂu-
ence some of the speciﬁc tissue functions within an engineered
tissue [35]. The major challenge in designing polymer-based scaf-
folds for tissue engineering is the tradeoff between adequate ma-
terial porosity and mechanical strength. Both mechanical
properties and pore size can be controlled by process parameters
such as pre-freezing temperature, cooling rate, concentration and
composition of polymer [36,37]. 5% CS/CMC scaffolds with 20%
MgG were found to have both the highest compressive strength
(0.38 MPa) and highest compressive modulus (6.9 MPa) among the
scaffolds studied. Compressive strength of natural hard tissue like
cancellous bone is (1e12) MPa. When the compressive modulus
was calculated, it was observed that polymer composition in-
ﬂuences the stiffness. A signiﬁcantly lower modulus was observed
in lower concentration CS scaffolds. This may be due to the differ-
ence in porosities and pore size between the scaffolds. A higher
pore volume and a larger pore size inside the lower concentration
scaffold provide the scaffold with a larger deformable space. Thus,
the scaffolds of 5 wt% composition, due to having small pore sizes,
are mechanically more desirable. Addition of MgG was found to
signiﬁcantly increase the mechanical properties. However, varia-
tion of MgG concentration between 5, 10 and 20% did not yield a
signiﬁcant difference in the mechanical strength. Higher concen-
tration of MgG did not contribute to the overall strength. This is
attributed to its interference with the phase separation of CS/CMC
solution during scaffold formation.
Magnesium (Mgþþ) is the fourth most abundant cation in the
body and affects many cellular functions including energy meta-
bolism, modulation of signal transduction, biomineralization of
bone and tooth, cell proliferation and differentiation. Upon contact
with aqueous solutions, the hydrophilic surface of MgG-containing
CS/CMC scaffold absorbs water and expands, releasing Mgþþ ions
from these hybrid scaffolds. In this study, over a period of 24 h, 75%
(1.3 mM) of magnesium ions was released from the scaffolds. In a
recent study by Jiali Wang et al., it was reported that for cell types
L929 and osteoblast, 35 mM and for BMSCs and MC3T3-E1, 15 mM
of Mg ion concentrations could be considered to be the critical dose
without inhibiting cell viability [38]. In other studies, Mg ions have
also been demonstrated to promote cell viability, differentiation,
migration and stimulate gene expressions [39,40]. The release
proﬁles contained two distinct regions: the ﬁrst being burst release
and the second, relatively constant release rate, after the initial
burst. The hydrophilic nature of CS/CMC, allows permeation of
water into the polymer matrix, and diffuses the Mgþþ ions from
scaffolds. Bulk-eroding polymers are often characterized by a burst
of drug release during the ﬁrst few hours of incubation, followed by
U. Adhikari et al. / Bioactive Materials 1 (2016) 132e139 139a slow, diffusion-controlled release [41]. To obtain a sustained
release of Mgþþ at a constant concentration from the surface of
scaffolds for a longer duration, an optimized polymer/MgG
composition and scaffold preparation technique will be needed.
The cell viability of these scaffold materials were assessed by
using a previously-established Alamar Blue (AB) as well as MTT
assay [28]. Comparison with cell viability on a control substrate
provides a relativemeasure of cell number. According to the current
ISO standards of Part 5, cell viability higher than 75% could be
considered with no toxic risks for medical devices, so we deﬁned
the Mgþþ ions concentration with 75% cell viability as the safety
level in our experiment [38]. All of the samples with MgG in this
experiment showed cell viability greater than 75% with 3T3 ﬁbro-
blast cells. The same scaffolds showed metabolic activities greater
than 100% with osteoblast cells.
5. Conclusions
Chitosan-magnesium-based composite scaffolds were success-
fully synthesized. The scaffold properties evaluated included
microporosity, mechanical strength and morphology. SEM analyses
showed that the scaffolds did have uniform porosity with pore sizes
in the range 50e250 mm. These pores were interconnected and
distributed in 3D networks throughout the scaffolds. The increase
of mechanical property values with increase in the wt% of CS/CMC
was determined to be statistically signiﬁcant. These observations
support the effectiveness of this new approach to prepare tissue-
engineered scaffolds. In vitro cytotoxicity studies showed that
these scaffolds are nontoxic and can provide adequate support for
cell growth and proliferation. The chitosan-MgG hybrid scaffold
mimicked the ECM of natural tissue physically and chemically, and
possessed high surface area, porosity, pore interconnectivity, and
excellent mechanical stability.
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